Krishnan Viswanadhan, Pharm.D., serves as Chief Corporate Development & Strategy Officer at Agios Pharmaceuticals Inc., where he drives the company's strategic initiatives, business development, and partnership opportunities to advance its mission in transforming the lives of patients with genetically defined diseases. With over 25 years of experience in the biopharmaceutical industry, Viswanadhan brings a unique blend of scientific expertise and commercial acumen. He earned his Doctor of Pharmacy from the University of Michigan and further honed his skills in computational chemistry and drug discovery through roles at leading firms such as Vertex Pharmaceuticals and Novartis, where he contributed to the discovery and development of multiple clinical candidates. Throughout his career, Viswanadhan has been instrumental in forging high-impact alliances and licensing deals that have accelerated innovation in oncology and rare metabolic disorders. Notable achievements include leading business development efforts at Servier, where he spearheaded global partnerships, and at bluebird bio, contributing to strategic expansions in gene therapy. His track record includes over $5 billion in successful transactions, earning him recognition as a key player in biotech deal-making. At Agios, Viswanadhan oversees corporate strategy, including mitapivat's recent approvals for pyruvate kinase deficiency and ongoing pipeline advancements. His leadership has positioned the company for sustained growth through targeted collaborations and M&A opportunities, leveraging Agios' expertise in cellular metabolism to deliver breakthrough therapies.